Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Pediatrix Medical Group Inc (NYSE: MD) closed at $9.94 in the last session, down -1.68% from day before closing price of $10.11. In other words, the price has decreased by -$1.68 from its previous closing price. On the day, 0.5 million shares were traded. MD stock price reached its highest trading level at $10.1 during the session, while it also had its lowest trading level at $9.83.
Ratios:
We take a closer look at MD’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.41 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.50. For the most recent quarter (mrq), Quick Ratio is recorded 1.38 and its Current Ratio is at 1.38. In the meantime, Its Debt-to-Equity ratio is 0.99 whereas as Long-Term Debt/Eq ratio is at 0.94.
On September 27, 2021, SVB Leerink started tracking the stock assigning a Mkt Perform rating and target price of $29.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 09 ’24 when Richards C Marc sold 32,562 shares for $10.08 per share. The transaction valued at 328,225 led to the insider holds 192,785 shares of the business.
Richards C Marc sold 17,438 shares of MD for $175,775 on Aug 12 ’24. The EVP, Chief Financial Officer now owns 175,347 shares after completing the transaction at $10.08 per share. On Aug 09 ’24, another insider, Wood Lee, who serves as the Former Officer of the company, bought 47,230 shares for $10.25 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MD now has a Market Capitalization of 853505984 and an Enterprise Value of 1405129984. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.43 while its Price-to-Book (P/B) ratio in mrq is 1.21. Its current Enterprise Value per Revenue stands at 0.702 whereas that against EBITDA is 7.402.
Stock Price History:
The Beta on a monthly basis for MD is 1.50, which has changed by -0.33154 over the last 52 weeks, in comparison to a change of 0.24822903 over the same period for the S&P500. Over the past 52 weeks, MD has reached a high of $15.00, while it has fallen to a 52-week low of $6.62. The 50-Day Moving Average of the stock is 28.10%, while the 200-Day Moving Average is calculated to be 12.83%.
Shares Statistics:
According to the various share statistics, MD traded on average about 1.33M shares per day over the past 3-months and 824550 shares per day over the past 10 days. A total of 85.87M shares are outstanding, with a floating share count of 84.49M. Insiders hold about 1.60% of the company’s shares, while institutions hold 101.17% stake in the company. Shares short for MD as of 1722384000 were 5781181 with a Short Ratio of 4.36, compared to 1719532800 on 5439472. Therefore, it implies a Short% of Shares Outstanding of 5781181 and a Short% of Float of 9.51.
Earnings Estimates
Current recommendations for the stock of the company come from 7.0 analysts. The consensus estimate for the next quarter is $0.37, with high estimates of $0.39 and low estimates of $0.34.
Analysts are recommending an EPS of between $1.32 and $1.15 for the fiscal current year, implying an average EPS of $1.26. EPS for the following year is $1.43, with 7.0 analysts recommending between $1.53 and $1.28.
Revenue Estimates
According to 7 analysts, the current quarter’s revenue is expected to be $507.09M. It ranges from a high estimate of $522.35M to a low estimate of $488.88M. As of the current estimate, Pediatrix Medical Group Inc’s year-ago sales were $506.61MFor the next quarter, 7 analysts are estimating revenue of $497.53M. There is a high estimate of $538.99M for the next quarter, whereas the lowest estimate is $461.69M.
A total of 7 analysts have provided revenue estimates for MD’s current fiscal year. The highest revenue estimate was $2.06B, while the lowest revenue estimate was $1.95B, resulting in an average revenue estimate of $2B. In the same quarter a year ago, actual revenue was $1.99BBased on 7 analysts’ estimates, the company’s revenue will be $1.99B in the next fiscal year. The high estimate is $2.14B and the low estimate is $1.86B.
